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Natural product compound collections have proven an effective way to access chemical diversity and recent findings have identified
phenolic, coumarin, and polyamine natural products as atypical chemotypes that inhibit carbonic anhydrases (CAs). CA enzymes
are implicated as targets of variable drug therapeutic classes and the discovery of selective, drug-like CA inhibitors is essential.
Just two natural product polyamines, spermine and spermidine, have until now been investigated as CA inhibitors. In this study,
five more complex natural product polyamines 1–5, derived from either marine sponge or fungi, were considered for inhibition
of six different human CA isozymes of interest in therapeutic drug development. All compounds share a simple polyamine core
fragment, either spermine or spermidine, yet display substantially different structure activity relationships for CA inhibition.
Notably, polyamines 1–5 were submicromolar inhibitors of the cancer drug target CA IX, this is more potent than either spermine
or spermidine.
1. Introduction
Carbonic anhydrases (CAs) catalyze the reversible hydration
of carbon dioxide to bicarbonate anion and a proton: CO
2
+
H
2
O 󴀗󴀰 HCO
3
− +H+ [1].This equilibrium underpins a range
of physiological processes including pH regulation, carbon
metabolism, and ion transport. The therapeutic potential
for modulating this reaction is well recognized across a
number of diseases affecting humans, with the discovery that
interfering with pH plays a major role in survival, growth,
and metastasis of hypoxic tumours driving a need for small
molecule CA inhibitors [2]. The active site of CA enzymes
comprises a zinc cation that is coordinated to three conserved
histidine residues and a hydroxide anion (OH−). The zinc-
bound OH− reacts with CO
2
to generate HCO
3
− and H+;
these ions are then rapidly released to the microenvironment
and the active enzyme is regenerated. The structural similar-
ities in active site architecture across human CA isozymes
are substantial and for drug discovery that is dependent
on selectively targeting specific CA isozymes this presents
a considerable hurdle [3]. Primary sulfonamide compounds
(R–SO
2
NH
2
) coordinate as an anion (R–SO
2
NH−) to the CA
active site zinc in place of the usual OH− anion and are highly
effective inhibitors of CAs. Many primary sulfonamide com-
pounds are however nonselective, resulting in broad acting
CA inhibitors that are a major drawback to drug discovery.
The identification of new CA inhibitor chemotypes with
better CA isozyme selectivity profiles is needed to address
this drawback. Natural product (NP) compound collections
have proven an effective way to access new chemotypes,
and notably NPs have provided a significant portion of
FDA approved drugs, particularly in the cancer therapeutics
drug class [4]. Recent findings have identified phenol, [5–7]
coumarin [8, 9], and polyamine [10] NPs that inhibit CAs.
Using protein X-ray crystallography researchers have shown
that each of these chemotypes interacts differently with the
CAactive site, andunlike primary sulfonamides none directly
interact with the active site zinc [11]. The number of NPs that
have so far been investigated for inhibition of CAs is however
small and just a single innovative study that describes the
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Figure 1: Natural product polyamine CA inhibitors, spermine and spermidine [10].
inhibition of CAs with simple NP polyamines, spermine
and spermidine, is reported (Figure 1) [10]. The inspiration
for the present study is to further examine NP polyamines,
particularly those with greater structural complexity than
spermine and spermidine. With so few polyamines investi-
gated for CA inhibitory activity, we hoped to broaden our
understanding of the potential of polyamine alkaloids as an
alternate nonclassical chemotype for CA inhibition.
Polyamines have been isolated from terrestrial and
marine animals, plants, fungi, and bacteria [12]. These poly-
cationic alkaloids are able to strongly interact with anionic
biomolecules such as DNA and RNA and to a lesser extent
proteins. This interaction may modulate a selection of cel-
lular activities including gene expression, cell proliferation,
translation, cell signaling, membrane stabilization, and ion
channels [13–18]. The CA activity for two of the simplest NP
polyamines, spermine and spermidine, and 16 semisynthetic
polyamine analogues has been reported [10]. In this study, the
inhibition of all 12 catalytically active human CA isozymes
was assessed and the variation in Ki values ranged from
low nanomolar to millimolar. The standout CA isozyme
was CA IV, a transmembrane anchored enzyme with an
extracellular orientated active site [19]. Both NP polyamines
achieved lower Ki values, 0.010𝜇M and 0.112 𝜇M for sper-
mine and spermidine, respectively, at CA IV compared to
all other tested CAs. An X-ray crystal structure of spermine
in complex with CA II showed that it binds differently
compared to primary sulfonamides. Spermine is a polycation
at the experimental pH (pH = 7.4) and was found indirectly
anchored to the zinc cation via the zinc-bound water ligand.
Furthermore, a complex network of hydrogen bonds between
spermine and CA active site residues was observed, including
the terminal amine moiety which forms hydrogen bonds
with residues Thr200 and Pro201. This CA binding mode
suggests that NP polyamines may have potential to provide
additional CA inhibitors with this altered mechanism of
binding and inhibition of CAs. As polycations, compounds
spermine and spermidine are not expected to enter cells by
passive membrane diffusion, and this may give them some
selectivity for extracellular facing CAs (CAs IV, IX, XII, and
XIV) in cell models, and these isozymes are the focus of the
present study.
2. Materials and Methods
2.1. Chemistry. Compounds were isolated from two marine
sponge samples and one mushroom specimen, archived in
the Nature Bank biota repository, [20] located at the Eskitis
Institute for DrugDiscovery, GriffithUniversity. Nature Bank
is a unique drug discovery resource that consists of >50,000
biota samples collected from Australia, China, and Papua
New Guinea along with >200,000 fractionated natural prod-
uct samples [21].The fiveNP polyamines (1–5) investigated in
this study were identified as previously reported NPs ianthel-
liformisamine A (1), ianthelliformisamine B (2), ianthelli-
formisamine C (3), spermatinamine (4), and pistillarin (5)
following NMR and MS data analysis and comparison with
literature values [17, 22–25]. Prior to biological evaluation all
compounds were subjected to purity analysis by 1H NMR
spectroscopy and shown to be >95%.
2.2. CA Inhibition Assay. An Applied Photophysics stopped-
flow instrument was used for assaying the CA-catalyzed
CO
2
hydration activity [26]. IC
50
values were obtained from
dose response curves working at seven different concentra-
tions of test compound; by fitting the curves using PRISM
(http://www.graphpad.com/) and nonlinear least squares
methods, values represent the mean of at least three different
determinations as described by us previously [27]. The inhi-
bition constants (Ki) were then derived by using the Cheng-
Prusoff equation [28] as follows: Ki = IC50/(1 + [S]/Km),
where [S] represents the CO
2
concentration at which the
measurement was carried out and Km is the concentration
of substrate at which the enzyme activity is at half maximal.
All enzymes used were recombinant, produced in E. coli as
reported earlier [29, 30].The concentrations of enzymes used
in the assay were as follows: hCA I, 10.2 nM; hCA II, 9.5 nM;
hCA IV, 8.9 nM; hCA IX, 8.7 nM; hCAXII, 10.9 nM; and hCA
XIV, 12.6 nM.
3. Results and Discussion
The Davis Group at Eskitis has built up a unique in-house
compound library over the past 10 years that currently
consists of 352 distinct structures, the majority of which
have been obtained from natural sources. Briefly, the NPs
in this collection have been isolated from endophytic fungi,
[31] macrofungi, [32] plants, [33], and marine invertebrates
(e.g., sponges [34] and ascidians [35]) with quantities ranging
from 0.4mg to >1 g. Approximately 15% of this library
contains semisynthetic NP analogues, [32, 36] while a small
percentage (∼5%) of the library is known commercial drugs
or synthetic compounds inspired by NPs. A substructure
search on this NP-based library against the spermidine
fragment identified five secondary metabolites as hits. These
included NP polyamines, ianthelliformisamines A–C (1–3),
[17] spermatinamine (4) [22], and pistillarin (5) [23–25]
(Figure 2), all of which have had various biological activities
reported, but no CA bioactivity. Ianthelliformisamines A–C
(1–3) were initially isolated from the marine sponge Suberea
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Figure 2: Natural product polyamines 1–5 sourced from the Davis compound library. Red: spermine core fragment and blue: spermidine
core fragment.
ianthelliformis and display varying levels of inhibitory activity
against the Gram-negative bacteria Pseudomonas aeruginosa
[17]. Specifically, ianthelliformisamine A (1) was the most
potent antibacterial agent from this particular series with an
IC
50
value of 6.8 𝜇M (MIC 35 𝜇M) [17]. Spermatinamine (4)
was originally isolated from the sponge Pseudoceratina sp.
and was the first NP inhibitor of isoprenylcysteine carboxyl
methyltransferase (ICMT), which catalyzes the carboxyl
methylation of oncogenic proteins in the final step of a
series of post-translational modifications [22]. ICMT has
been proposed as an attractive and novel anticancer target
[22].More recently spermatinamine (4) and a series of related
NPs have been shown to inhibit Gram-negative bacteria [18].
Pistillarin (5) has been isolated from a variety of fungal
species including Penicillium bilaii [23], Gomphus floccosus
[24], Clavariadelphus pistillaris [25], and several Ramaria
species [25, 32] and is a known siderophore [37]. In addition,
compound 5 has recently been shown to exhibit significant
protective effects against DNA damage caused by hydroxyl
radicals generated from the Fenton reaction via iron chelation
and to exhibit free radical-scavenging activity [24]. Pistillarin
(5) and NP polyamines 1–4 have all recently been evaluated
for their antimalarial activity, [32] with 4 and 5 identified as
the most potent polyamines towards a drug sensitive Plas-
modium falciparum parasite line (3D7) with IC
50
values of
0.23 and 1.9 𝜇M, respectively. These complex NP polyamines
1–5 (Figure 2) form the basis of the present paper wherein we
describe the CA inhibition against six human CA isozymes.
The inhibition activity data for the simple NP polyamines
spermine and spermidine reported earlier and the more
complex NP polyamines 1–5 against six human CA isozymes
of interest in therapeutic drug development is presented
in Table 1. CA I and CA II are the predominant off-
target isozymes (there are exceptions, e.g., CA inhibitors as
antiglaucoma agents), while CAs IV, IX, XII, and XIV all
have an extracellular oriented active site. CA IX and CA XII
are overexpressed in many tumors [38, 39], CA IV plays a
role in eye and kidney pathology [40, 41], while CA XIV
is less well studied but has a role in a number of organs
[42]. Polyamines 1, 3, and 4 comprise the polyamine frag-
ment [–NH–(CH
2
)
3
–NR–(CH
2
)
4
–NR–(CH
2
)
3
–NH–] that is
present in spermine (R = H), while polyamines 2 and 5
comprise the shorter polyamine chain [–NH–(CH
2
)
3
–NH–
(CH
2
)
4
–NH–] of spermidine. Compounds 1 and 2 are deriva-
tized at one terminal amine group of the base polyamine frag-
ment with the other terminal amine unmodified, while com-
pounds 3–5 are derivatized at both terminal amine groups
and so lack a primary amine end group. Polyamines 1–4 are
metabolites derived from bromotyrosine, with compound 4
comprising even further structural complexity including two
oxime groups and methylation of the two central amines
resulting in tertiary amines in place of secondary amines
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Table 1: Inhibition data of human CA isozymes with simple natural product polyamines: spermine and spermidine [10] and complex natural
product polyamines 1–5 and the clinically used CA inhibitor, acetazolamide.
Polyamine 𝐾𝑖 (𝜇M)
a
CA I CA II CA IV CA IX CA XII CA XIV
Spermine 231 84 0.010 13.3 27.6 0.86
Spermidine 1.40 1.11 0.112 1.37 44.1 1.00
1 1.76 0.41 6.72 0.20 2.81 2.12
2 0.77 0.37 9.10 0.35 3.48 2.28
3 0.86 0.35 9.08 0.27 3.50 6.96
4 0.85 0.48 >20 0.34 >20 2.72
5 0.79 0.34 7.03 0.36 4.21 1.52
Acetazolamide 0.25 0.012 0.074 0.025 0.006 0.041
aErrors in the range of ±5% of the reported value, from three determinations using a stopped-flow CO2 anhydrase assay.
within the central polyamine fragment. Polyamine 5 differs to
compounds 1–4 as it comprises two catechol end groups. As
both catechol and oxime moieties feature in the structure of
known metal ion chelators [43, 44] polyamines 4 and 5 have
the potential for a companion action to any bioactivity based
on CA enzyme inhibition.
The polyamines spermine and spermidine have two
primary amine end groups and a flexible, linear polyamine
backbone. In contrast, as described above, compounds 1–5
are more complex in structure and these structural differ-
ences result in considerably altered SAR for 1–5 compared
to the simpler NP fragments (Table 1). There are a number
of general SAR trends of 1–5 that differ; these include (i)
∼200-fold greater inhibition of off-target CA I and CA II than
spermine, yet similar CA I and CA II inhibition to the shorter
chain spermidine, (ii) inhibition of both the cancer associated
CA isozymes CA IX and CA XII in the submicromolar
range, which is better than both spermine and spermidine,
and (iii) generally inhibit the other two extracellular CAs,
CA IV and CA XIV, more weakly than both spermine and
spermidine. Polyamine 4 has greater structural complexity
than all other polyamines of this study and has much weaker
inhibition of CA IV and CA XII (>20𝜇M), and this indicates
that the greater complexity lessens the binding interaction
with CA IV and CA XII. It is interesting that this lessened
activity is not observed for the other four CAs, suggesting
that the structural features of 4 may be interacting at CA
active site hot spots [45]. Compounds 1 and 2 are modified
at only one terminal amine of the base polyamine fragment
yet have very similar SAR to compounds 3 and 5 that are
modified at each end and lack a primary amine group. This
SAR suggests that it may be the combination of both primary
amine end groups of spermine and spermidine that underpin
their differing CA enzyme inhibition profile. Future efforts
from our groups will employ protein X-ray crystallography
and molecular modelling to investigate if altered binding
orientations of these NP polyamines do contribute to the
differing SAR observed.
4. Conclusions
The discovery of new CA inhibitors with an alternate
mechanism of inhibition to classical zinc binding functional
groups can benefit from the unique chemical diversity pro-
vided in NP compound collections and so far is relatively
underexplored. The structural features of polyamines 1–5
in this study, compared to the much simpler polyamine
fragments of spermine and spermidine, further contribute to
our understanding of the potential of both NPs and alternate
chemotypes to contribute useful ligands to better enable the
direction of the CA drug discovery field.
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